ABSTRACT
O R I G I N A L P A P E R in antenatal care, HDP remain one of the leading causes of maternal mortality and morbidity [1] [2] [3] . HDP are a significant burden on women's lives and healthcare systems, not only because of the associated adverse pregnancy outcomes, but also because of an increased need for antenatal surveillance. The UK National Institute for Health and Care Excellence (NICE) guidelines recommend regular blood-pressure measurements in pregnant women with hypertension 4 . The frequency of surveillance depends on the severity of hypertension and background risk of pre-eclampsia, but it usually involves a minimum of one or two measurements per week for mild and moderate hypertension 4 . The importance of these visits for the prevention of maternal death is emphasized in a recent maternal, newborn and infant clinical outcome (MBRRACE) report 5 . Recent evidence suggests that home blood-pressure monitoring (HBPM) could be a viable, and possibly superior, alternative to the standard clinical management of adults with chronic hypertension, but the evidence for its use in pregnancy is limited 6, 7 . The potential benefits of HBPM in pregnancy include earlier detection of pre-eclampsia, convenience for the pregnant woman and reduced healthcare costs, as well as increased compliance with and acceptance of monitoring [8] [9] [10] [11] . Our recent work has demonstrated that HBPM reduces the number of hospital visits without compromising maternal and fetal outcomes 9 . Furthermore, HBPM was found to be cost-effective, with an average saving per week of £286.53 in the group of women following HBPM using a dedicated app, compared with those undergoing traditional monitoring at the hospital/clinic 8 . Despite these potential benefits, only a limited number of studies have compared blood-pressure values recorded at home with those recorded at the clinic, with conflicting results reported [12] [13] [14] [15] [16] [17] . The aim of this study was to assess the agreement of HBPM and clinic blood-pressure measurements in a cohort of pregnant women with HDP.
METHODS
This was a cohort study of women with HDP conducted between June 2016 and December 2017 at St George's Hospital, University of London, London, UK. Inclusion criteria were chronic hypertension, gestational hypertension or high risk of developing pre-eclampsia, no significant proteinuria (≤ 1+ proteinuria on dipstick testing) and no hematological or biochemical abnormalities. Exclusion criteria were maternal age < 16 years, systolic blood pressure > 155 mmHg, diastolic blood pressure > 100 mmHg, significant proteinuria (≥ 2+ on dipstick testing or protein/creatinine ratio ≥ 30 mg/mmoL), estimated fetal weight < 10 th centile, signs of severe pre-eclampsia (oliguria < 500 mL/24 h, cerebral or visual disturbance, pulmonary edema, epigastric or right-upper quadrant pain, impaired liver function, platelet count < 100 000/mm 3 ), significant mental health concerns or insufficient understanding of the English language. Women presented via referral to the hypertension clinic or the day assessment unit. Those who satisfied the inclusion criteria were invited to participate in the study and perform HBPM.
Eligible patients were counseled and trained by a specialist midwife and supplied with an automated Microlife ® 'WatchBP Home' blood-pressure machine (MicrolifeCorporation, Taipei, Taiwan), which has been validated for use in pregnancy and pre-eclampsia 18 . The same blood-pressure device was used to record the participants' blood pressure at the hospital. Women were taught how to measure their blood pressure accurately and record readings in their notes or on a specially designed smartphone app (Hampton Medical ® , Trakka Medical, UK; downloadable at https://itunes.apple.com/us/ app/hampton-medical/id1328312740?mt=8). Moreover, women were advised about blood-pressure measuring conditions, such as avoiding excessive consumption of stimulant drinks (i.e. coffee), resting for at least 5 min before measuring, sitting with the back supported and the feet flat on the floor, keeping the arm at the level of the heart and removing tight or excessive layers of clothing. Each patient was prescribed a personalized schedule of hospital visits and blood-pressure measurements according to their individual risk as per NICE guidelines 4 . The blood-pressure measurements performed at home and those obtained at the corresponding hospital visit for that gestational age were paired for analysis. The HBPM reading obtained closest to the clinic visit was chosen for analysis, and when more than one measurement was available from the same day, the observation for analysis was chosen randomly using a computer algorithm that generates a random number from a discrete uniform distribution (U∼1,n; n = number of available observations).
Data on maternal age and body mass index at booking, parity, self-reported ethnicity, mode of conception, smoking status and type of HDP at booking and at delivery were collected. The diagnosis of gestational hypertension or pre-eclampsia was made according to the criteria of the International Society for the Study of Hypertension in Pregnancy 19 . Gestational hypertension was diagnosed in the presence of systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg on at least two occasions 4 h apart in the absence of proteinuria, after 20 weeks' gestation in a previously normotensive woman. Pre-eclampsia was diagnosed when gestational hypertension was complicated by significant proteinuria (≥ 2+ protein on dipstick testing or protein/creatinine ratio ≥ 30 mg/mmoL). Superimposed pre-eclampsia was considered when symptoms of pre-eclampsia were present in women with chronic hypertension (presence of hypertension before 20 weeks' gestation). Clinically significant hypertension was defined as either hypertension which would require pharmaceutical intervention or inadequately controlled hypertension under medication as per NICE guidelines (> 149 mmHg systolic or > 99 mmHg diastolic pressure) 4 . White-coat hypertension was diagnosed when clinic measurements were consistently higher than normal home measurements. Ethical approval was obtained for the study (16/NW/0206).
Statistical analysis
Continuous variables are presented as median (interquartile range (IQR)). Binary and categorical variables are presented as n (%). Distribution assumptions for continuous variables were visually assessed using quartile-quartile plots, and then confirmed using the Shapiro-Wilk test. Differences between home and clinic blood-pressure measurements were tested using the Wilcoxon signed rank test or paired t-test, and differences were also assessed visually using Bland-Altman plots 20, 21 . Comparison of the binary outcomes was performed with McNemar's chi-square test. Only one pair of measurements (one obtained at the clinic and the closest one obtained at home) was used per patient. Subgroup analysis was performed in the following gestational age windows: < 14, 15-22, 23-32 and 33-42 weeks' gestation; P < 0.05 was considered to indicate statistical significance. Statistical analysis was performed using R for Statistical Computing Software ® (Version 3.4.2) 22 . GraphPad Prism for Windows (La Jolla, CA, USA) software was used to obtain some of the figures.
RESULTS
A total of 294 blood-pressure measurements from 147 women were included in the analysis. Median maternal age at the time of enrollment was 34.0 (IQR, 29.5-38.0) years. The study cohort consisted predominantly of Caucasian women (90/147 (61.2%)), but other ethnic backgrounds were also represented ( Table 1 ). The initial diagnosis at enrollment was chronic hypertension, gestational hypertension, history of HDP pregnancy and white-coat hypertension in 21.1%, 72.8%, 5.4% and 0.7% of women, respectively. The final diagnosis at delivery was chronic hypertension, gestational hypertension, pre-eclampsia and normotensive in 18.4%, 55.1%, 21.8% and 4.7% of women, respectively. Median systolic blood-pressure measurements obtained at home were significantly lower than those obtained at the clinic (132.0 (IQR, 123.0-140.0) mmHg vs 138.0 (IQR, 132.0-146.5) mmHg; P < 0.001) ( Table 2) . When stratified according to gestational age, median systolic blood-pressure measurements at home were significantly lower than those obtained at the clinic in all gestational-age windows explored, except in the period 23-32 weeks' gestation (P = 0.057) (Figure 1a ). Mean differences were 7.30 mmHg lower in HBPM when averaged across all gestational ages, but the limits of agreement (LOA) were wide (95% LOA, -35.64 mmHg to 21.02 mmHg) (Figure 2a ). Subgroup analysis by gestational age showed that the difference was greater earlier in pregnancy (mean difference of 11.2 mmHg at 5-22 weeks) compared with that at later gestational ages (mean difference of 5.09 mmHg at 23-32 weeks and 6.00 mmHg at 33-42 weeks) (Figures S1a, S2a and S3a).
Median diastolic blood-pressure measurements obtained at home were also significantly lower than those obtained at the clinic (85.0 (IQR, 77.0-90.0) mmHg vs 89.0 (IQR, 82.0-94.0) mmHg; P < 0.001) ( Table 2) . When stratified according to gestational age, diastolic HBPM measurements were significantly lower than clinic measurements in the periods 5-14 weeks (P < 0.001), 15-22 weeks (P = 0.008) and 33-42 weeks (P < 0.001) (Table 2, Figure 1b) . Mean differences were 4.27 mmHg lower in HBPM when averaged across all gestational ages, but the LOA were wide (95% LOA, -21.89 to 13.35 mmHg) (Figure 2b ). Subgroup analysis by gestational age showed a greater difference at earlier gestational ages (mean difference of 6.48 mmHg at 5-22 weeks) compared with later ones (mean difference of 5.09 mmHg at 23-32 weeks and 4.18 mmHg at 33-42 weeks) (Figures S1b, S2b and S3b).
The incidence of clinically significant systolic (19.7% clinic vs 4.8% HBPM; P < 0.001) and diastolic (11.6% clinic vs 2.7% HBPM; P = 0.005) hypertension was four to five times higher based on clinic blood-pressure measurements than when based on HBPM (Table 3) . Subgroup analysis by gestational epochs revealed similar results (Table 3) .
DISCUSSION

Summary of main findings
Both systolic and diastolic blood-pressure measurements at home were significantly lower than those recorded in the clinic. The incidence of clinically significant hypertension was four to five times lower based on measurements recorded at home compared with in the clinic.
Interpretation of study findings and comparison with existing literature
Our finding of lower median blood-pressure recordings at home is in agreement with published evidence in non-pregnant hypertensive adults 23, 24 . Studies in pregnant women have demonstrated conflicting results, with some reporting lower home blood-pressure measurements and others no difference between HBPM and clinic measurements [12] [13] [14] [15] [16] [17] 25 . The monitoring schedules, risk status of the included women and gestational-age periods varied greatly between these studies 12, 15, 17 . In contrast to our study, most of these studies used devices that are not validated for use in pregnancy, which might be another potential explanation for the heterogeneity observed in the literature [12] [13] [14] [15] . The Microlife WatchBP monitor used in our study has been validated in pregnancy and in pre-eclampsia, with a mean difference of -2.6 ± 7.0 mmHg for systolic and 0.8 ± 4.4 mmHg for diastolic blood pressure in pre-eclampsia 18 . We used the same monitor for home and clinic measurements and the time interval was not fixed for paired readings.
Significant variation between HBPM and clinic measurements is reported in the literature 26 , as observed in our study. This variation could be due to random time intervals between home blood-pressure measurements and clinic readings, nocturnal variation, 'white-coat effect' or seasonal variation [26] [27] [28] [29] [30] . It is also probable that women are more relaxed at home, with a higher parasympathetic drive lowering the baseline heart rate and systolic blood pressure. Time interval, as a surrogate for blood-pressure variability, has been reported as an important confounder for studies exploring agreement between two devices/methods and it is likely to be the main factor explaining the variation 12, 26, 31 . In the absence of such confounders, the Microlife WatchBP is a reliable monitor and has been validated in pregnant and non-pregnant adult populations 18, 32, 33 . Importantly, we have identified that the incidence of clinically significant hypertension differs according to whether measurements are obtained at home or in a clinic setting. This is a relevant finding, as a lower incidence of clinically significant hypertension in HBPM could be explained in two ways. One possibility is that HBPM could miss cases with severe hypertension, and therefore potentially lead to increased adverse pregnancy outcomes; however, our recently published data do not support this concern 9 . The other possibility is that HBPM is more accurate than is hospital blood-pressure measurement, as has been demonstrated recently in the non-pregnant population 34 . This may be explained, at least in part, by the avoidance of white-coat hypertensive readings in hospital. It seems likely that lower and more accurate blood-pressure readings obtained at home could reduce unnecessary medical interventions, such as antihypertensive therapy and induction of labor, and could potentially have a positive effect on patients' experience, use of healthcare resources and costs 8, 10, 35, 36 .
Clinical and research implications
Home and ambulatory monitoring is recommended for managing hypertension in non-pregnant adults 37, 38 . Although HBPM is likely to be the ideal way of managing HDP, national and international guidelines have not yet recommended it, most probably in view of the limited evidence for its use in pregnant women 38, 39 . Furthermore, the number of validated devices that can be used in pregnancy and pre-eclampsia is limited 40, 41 . Therefore, more studies are needed to address a number of questions related to the safety of HBPM, appropriate thresholds for referral to the hospital and whether this method would lead to earlier detection of pre-eclampsia compared with traditional blood-pressure monitoring.
Some guidelines suggest that lower thresholds should be used for home measurements 37 . However, the optimal blood-pressure threshold for predicting adverse outcomes in pregnancy is yet to be established, and using lower cut-offs may increase the number of false-positive results. Identification of clinically relevant thresholds for HBPM that improve pregnancy outcomes, or at least do not increase the risk of complications, compared with the currently used blood-pressure thresholds, is important.
HBPM allows a higher number of blood-pressure recordings to be obtained without additional cost. In adults with chronic hypertension, it is recommended that diagnosis and decision-making should be based on the average value of all HBPM measurements, excluding the first reading 37 . Whether this is an acceptable management option for pregnant women is unknown. The optimal number of measurements per day and the surveillance interval per week are yet to be established for HBPM and it is likely that an individualized approach is required.
Strengths and limitations
This is one of the few studies using a validated blood-pressure device in pregnant women and in pre-eclampsia, to compare home vs hospital/clinic blood-pressure measurements. The use of a validated device is quite important, as pregnancy-induced vascular changes, especially in HDP, could affect the blood-pressure measurements, rendering commonly available devices of little use in pregnancies complicated by HDP 42, 43 . An effort is now being made to standardize the validation criteria for such devices 44 . Moreover, our cohort consisted mainly of women with a confirmed diagnosis of HDP, in contrast to other studies which recruited patients at high or undetermined risk of developing HDP 12, 14, 25 . This is likely to enhance the clinical relevance of our findings, as HBPM has been used so far mainly in women with HDP.
A potential pitfall of HBPM is the inaccuracy of patient-reported blood-pressure recordings 29, 45 . The use of telemetry has been shown to improve the accuracy of blood-pressure recordings 45 . Automated linkage between the blood-pressure device and smartphones, e.g. using Bluetooth technology, can overcome this concern. Another limitation of our study is the small number of patients in the first trimester. This is to be expected given the low prevalence of chronic hypertension in pregnant women. Most of the published studies did not include measurements before 20 weeks' gestation from patients who suffer exclusively from chronic hypertension 14, 15, 30 . Therefore, despite the small number in our study, the data could provide valuable information. Even though the women were prescribed a standard regimen for medication intake and blood-pressure measurements, deviations from the prescribed regime may have contributed to the blood-pressure differences observed in our study.
Conclusions
Both systolic and diastolic blood-pressure values were lower when recorded at home than when recorded in a clinic. Moreover, the incidence of clinically significant hypertension was lower when based on recordings performed at home compared with that based on recordings in the clinic. HBPM has the potential to reduce unnecessary medical interventions in women with HDP. Prospective studies investigating the use of HBPM in pregnant women are urgently needed to determine the relevant blood-pressure thresholds for HBPM, and interval and frequency of monitoring.
